Speiser, D. E., Ho, P.-C. & Verdeil, G. Regulatory circuits of T cell operate in most cancers. Nat. Rev. Immunol. 16, 599–611 (2016).
Proost, P. et al. Amino-terminal truncation of CXCR3 agonists impairs receptor signaling and lymphocyte chemotaxis, whereas preserving antiangiogenic properties. Blood 98, 3554–3561 (2001).
Vanheule, V., Metzemaekers, M., Janssens, R., Struyf, S. & Proost, P. How post-translational modifications affect the organic exercise of chemokines. Cytokine 109, 29–51 (2018).
Casrouge, A. et al. Proof for an antagonist type of the chemokine CXCL10 in sufferers chronically contaminated with HCV. J. Clin. Make investments. 121, 308–317 (2011).
Cho, S. Y. et al. The impact of CXCL12 processing on CD34+ cell migration in myeloproliferative neoplasms. Most cancers Res. 70, 3402–3410 (2010).
Barreira da Silva, R. et al. Dipeptidylpeptidase Four inhibition enhances lymphocyte trafficking, bettering each naturally occurring tumor immunity and immunotherapy. Nat. Immunol. 16, 850–858 (2015).
Lam, C. S.-C. et al. Prognostic significance of CD26 in sufferers with colorectal most cancers. PLoS ONE 9, e98582 (2014).
Liang, P.-I. et al. DPP4/CD26 overexpression in urothelial carcinoma confers an impartial prognostic influence and correlates with intrinsic organic aggressiveness. Oncotarget eight, 2995–3008 (2017).
Yamaguchi, U. et al. Distinct gene expression-defined lessons of gastrointestinal stromal tumor. J. Clin. Oncol. 26, 4100–4108 (2008).
Carretero, R. et al. Eosinophils orchestrate most cancers rejection by normalizing tumor vessels and enhancing infiltration of CD8+ T cells. Nat. Immunol. 16, 609–617 (2015).
Munitz, A. & Levi-Schaffer, F. Eosinophils: ‘new’ roles for ‘outdated’ cells. Allergy. 59, 268–275 (2004).
Kubo, H., Loegering, D. A., Adolphson, C. R. & Gleich, G. J. Cytotoxic properties of eosinophil granule main primary protein for tumor cells. Int. Arch. Allergy Immunol. 118, 426–428 (1999).
Zhang, H. & Verkman, A. S. Eosinophil pathogenicity mechanisms and therapeutics in neuromyelitis optica. J. Clin. Make investments. 123, 2306–2316 (2013).
Krishna, M. C. et al. Do nitroxide antioxidants act as scavengers of O2−. or as SOD mimics? J. Biol. Chem. 271, 26026–26031 (1996).
Rothenberg, M. E. & Hogan, S. P. The eosinophil. Annu. Rev. Immunol. 24, 147–174 (2006).
Gatault, S., Legrand, F., Delbeke, M., Loiseau, S. & Capron, M. Involvement of eosinophils within the anti-tumor response. Most cancers Immunol. Immunother. 61, 1527–1534 (2012).
Struyf, S. et al. CD26/dipeptidyl-peptidase IV down-regulates the eosinophil chemotactic efficiency, however not the anti-HIV exercise of human eotaxin by affecting its interplay with CC chemokine receptor three. J. Immunol. 162, 4903–4909 (1999).
Proost, P. et al. Amino-terminal truncation of chemokines by CD26/dipeptidyl-peptidase IV. Conversion of RANTES right into a potent inhibitor of monocyte chemotaxis and HIV-1-infection. J. Biol. Chem. 273, 7222–7227 (1998).
Forssmann, U. et al. Inhibition of CD26/dipeptidyl peptidase IV enhances CCL11/eotaxin-mediated recruitment of eosinophils in vivo. J. Immunol. 181, 1120–1127 (2008).
Wasmer, M.-H. & Krebs, P. The function of IL-33-dependent irritation within the tumor microenvironment. Entrance. Immunol. 7, 682 (2016).
Johnston, L. Ok. et al. IL-33 precedes IL-5 in regulating eosinophil dedication and is required for eosinophil homeostasis. J. Immunol. 197, 3445–3453 (2016).
Gao, X. et al. Tumoral expression of IL-33 inhibits tumor development and modifies the tumor microenvironment by way of CD8+ T and NK cells. J. Immunol. 194, 438–445 (2015).
Tepper, R. I., Coffman, R. L. & Leder, P. An eosinophil-dependent mechanism for the antitumor impact of interleukin-Four. Science 257, 548–551 (1992).
Mattes, J. et al. Immunotherapy of cytotoxic T cell-resistant tumors by T helper 2 cells: an eotaxin and STAT6-dependent course of. J. Exp. Med. 197, 387–393 (2003).
Lucarini, V. et al. IL-33 restricts tumor development and inhibits pulmonary metastasis in melanoma-bearing mice by way of eosinophils. Oncoimmunology 6, e1317420 (2017).
Bousquet, J. et al. Eosinophilic irritation in bronchial asthma. N. Engl. J. Med. 323, 1033–1039 (1990).
Ma, W. et al. CCR3 is important for pores and skin eosinophilia and airway hyperresponsiveness in a murine mannequin of allergic pores and skin irritation. J. Clin. Make investments. 109, 621–628 (2002).
Crapster-Pregont, M., Yeo, J., Sanchez, R. L. & Kuperman, D. A. Dendritic cells and alveolar macrophages mediate IL-13-induced airway irritation and chemokine manufacturing. J. Allergy Clin. Immunol. 129, 1621–7.e3 (2012).
Wills-Karp, M. et al. Interleukin-13: central mediator of allergic bronchial asthma. Science 282, 2258–2261 (1998).
Corren, J. et al. Lebrikizumab therapy in adults with bronchial asthma. N. Engl. J. Med. 365, 1088–1098 (2011).
Wenzel, S., Wilbraham, D., Fuller, R., Getz, E. B. & Longphre, M. Impact of an interleukin-Four variant on late section asthmatic response to allergen problem in asthmatic sufferers: outcomes of two section 2a research. Lancet 370, 1422–1431 (2007).
Shiobara, T. et al. Dipeptidyl peptidase-Four is very expressed in bronchial epithelial cells of untreated bronchial asthma and it will increase cell proliferation together with fibronectin manufacturing in airway constitutive cells. Respir. Res. 17, 28 (2016).
Zhen, G. et al. IL-13 and epidermal development issue receptor have important however distinct roles in epithelial cell mucin manufacturing. Am. J. Respir. Cell Mol. Biol. 36, 244–253 (2007).
Brightling, C. E. et al. Efficacy and security of tralokinumab in sufferers with extreme uncontrolled bronchial asthma: a randomised, double-blind, placebo-controlled, section 2b trial. Lancet Respir. Med. three, 692–701 (2015).
Samoszuk, M. et al. Elevated blood clotting, microvascular density, and irritation in eotaxin-secreting tumors implanted into mice. Am. J. Pathol. 165, 449–456 (2004).
Reichman, H., Karo-Atar, D. & Munitz, A. Rising roles for eosinophils within the tumor microenvironment. Tendencies Most cancers 2, 664–675 (2016).
Dorta, R. G. et al. Tumour-associated tissue eosinophilia as a prognostic think about oral squamous cell carcinomas. Histopathology 41, 152–157 (2002).
Fernández-Aceñero, M. J., Galindo-Gallego, M., Sanz, J. & Aljama, A. Prognostic affect of tumor-associated eosinophilic infiltrate in colorectal carcinoma. Most cancers 88, 1544–1548 (2000).
Costello, R., O’Callaghan, T. & Sébahoun, G. Eosinophils and antitumour response. Rev. Med. Interne. 26, 479–484 (2005).
Caruso, R. A. et al. Ultrastructural descriptions of heterotypic aggregation between eosinophils and tumor cells in human gastric carcinomas. Ultrastruct. Pathol. 35, 145–149 (2011).
Stenfeldt, A.-L. & Wennerås, C. Hazard alerts derived from burdened and necrotic epithelial cells activate human eosinophils. Immunology 112, 605–614 (2004).
Griesenauer, B. & Paczesny, S. The ST2/IL-33 axis in immune cells throughout inflammatory ailments. Entrance. Immunol. eight, 475 (2017).
Bourgeois, E. et al. The professional-Th2 cytokine IL-33 immediately interacts with invariant NKT and NK cells to induce IFN-γ manufacturing. Eur. J. Immunol. 39, 1046–1055 (2009).
Bonilla, W. V. et al. The alarmin interleukin-33 drives protecting antiviral CD8+ T cell responses. Science 335, 984–989 (2012).
Oboki, Ok., Nakae, S., Matsumoto, Ok. & Saito, H. IL-33 and airway irritation. Allergy Bronchial asthma Immunol. Res. three, 81–88 (2011).
Vasanthakumar, A. et al. The transcriptional regulators IRF4, BATF and IL-33 orchestrate improvement and upkeep of adipose tissue-resident regulatory T cells. Nat. Immunol. 16, 276–285 (2015).
Lu, B., Yang, M. & Wang, Q. Interleukin-33 in tumorigenesis, tumor immune evasion, and most cancers immunotherapy. J. Mol. Med. 94, 535–543 (2016).
Kim, J. et al. Intratumorally establishing sort 2 innate lymphoid cells blocks tumor development. J. Immunol. 196, 2410–2423 (2016).
Jovanovic, I. et al. ST2 deletion enhances innate and bought immunity to murine mammary carcinoma. Eur. J. Immunol. 41, 1902–1912 (2011).
Xiao, P. et al. Interleukin 33 in tumor microenvironment is essential for the buildup and performance of myeloid-derived suppressor cells. Oncoimmunology 5, e1063772 (2016).